Pharmacological effects and application fields of palbociclib/palbociclib

Palbociclib/Pabociclib, developed by Pfizer, is a treatment drug specifically for hormone receptor-positive, HER2-negative breast cancer. This drug is particularly useful in treating cases of breast cancer that are advanced or have spread (metastasized) in the body.

Palbociclib is often used in combination with hormonal therapies such as aromatase inhibitors. Palbociclib in combination with an aromatase inhibitor is considered an effective first-line treatment option for postmenopausal women or men who have not yet received hormone therapy. When a patient's condition worsens after taking an aromatase inhibitor, palbociclib can also be used in combination with fulvestrant to control the condition.

In clinical studies, the combination of palbociclib and letrozole has shown significant efficacy in postmenopausal women. Palbociclib belongs to the CDK 4/6 inhibitor class of drugs, which slows down the cell division process that leads to the growth of new cancer cells by blocking the activity of cyclin-dependent kinase (CDK) 4 and 6. Certain cancer types, such as hormone receptor-positive breast cancer, tend to have overactive and unregulated CDK4/6 activity, making palbociclib an effective treatment for these cancers.

Studies show that palbociclib can extend the time patients live before their cancer spreads. However, more clinical evidence is still needed to confirm its impact on overall survival. When treating palbociclib, it is usually recommended to use it in combination with other drugs (such as aromatase inhibitors or fulvestrant) and to take it continuously for 21 days. This treatment cycle is repeated every 28 days and can be continued as long as the patient responds positively to the drug and tolerates its side effects.